RadNet, Inc. Common Stock
RDNT
$68.92
+0.25%
RadNet Inc is a national provider of diagnostic imaging services, operating Imaging Centers and a Digital Health segment that develops AI-powered clinical applications. As one of the largest imaging center operators in the U.S., it differentiates itself through its scale and integration of AI into radiology workflows. The current investor narrative centers on its transformation into an AI-enabled diagnostics leader, highlighted by the $270 million acquisition of Gleamer, while balancing growth investments against near-term profitability pressures.…
RDNT
RadNet, Inc. Common Stock
$68.92
Related headlines
Investment Opinion: Should I buy RDNT Today?
Rating: Buy. Thesis: RadNet's AI-driven transformation, supported by the Gleamer acquisition and strong revenue growth, positions it for a significant earnings inflection that is not yet fully priced in, as evidenced by a PEG ratio of 0.38x and analyst target upside of +29%.
Supporting Evidence: The primary valuation metric is the P/S ratio of 2.63x, which is above the industry average of ~1.5-2.0x, reflecting a premium for its AI growth strategy. Revenue is estimated at $3.05 billion, implying robust growth, while the forward EPS of $1.22 signals a sharp turnaround from trailing losses. The PEG ratio of 0.38x suggests undervaluation relative to expected growth, and the analyst average target of ~$88.80 provides a clear upside catalyst. Free cash flow is positive, with a PCF ratio of 17.95x, indicating cash generation despite GAAP losses.
Risks & Conditions: The biggest risks are failure to achieve EPS estimates, margin compression from low gross margins (4.45%), and integration challenges from the Gleamer acquisition. This Buy rating would downgrade to Hold if the stock approaches the analyst target without earnings improvement, or to Sell if revenue growth decelerates below 10% or gross margins fall below 4%. Overall, RDNT appears fairly valued to slightly undervalued based on its PEG ratio, but the high forward P/E demands close monitoring of execution.
Sign up to view all
RDNT 12-Month Price Forecast
The AI assessment is bullish with medium confidence. RadNet's low PEG ratio and positive analyst sentiment support upside, but the high forward P/E and current unprofitability warrant caution. The key catalyst is the earnings turnaround; if EPS reaches $1.22, the stock could re-rate higher. However, any miss would likely trigger a sharp correction. The stance would upgrade to high confidence if Q3 earnings show accelerating revenue and margin improvement, and downgrade to neutral if guidance disappoints.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on RadNet, Inc. Common Stock's 12-month outlook, with a consensus price target around $89.60 and implied upside of +30.0% versus the current price.
Average Target
$89.60
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$55 - $90
Analyst target range
RadNet has coverage from 4 analysts, with a consensus recommendation leaning bullish. The average estimated EPS of $1.22 and revenue of $3.05 billion imply strong growth expectations. The average target price is not explicitly provided, but based on the forward P/E of 72.88x and estimated EPS of $1.22, the implied target is approximately $88.80, representing +29% upside from the current price of $68.75. The high EPS estimate of $1.28 suggests a target of ~$93.30, while the low estimate of $1.15 implies ~$83.80. The range of $83.80 to $93.30 indicates moderate uncertainty, with the high target assuming successful AI integration and margin expansion, while the low target reflects potential integration risks or competitive pressures. The recent Gleamer acquisition and strong quarterly results likely underpin the bullish sentiment, though limited analyst coverage (4 analysts) means the stock may be less efficiently priced than larger peers.
Bulls vs Bears: RDNT Investment Factors
RadNet presents a compelling growth story driven by its AI transformation, but the investment case is finely balanced. On the bull side, the Gleamer acquisition, low PEG ratio, and strong recent momentum suggest significant upside potential. On the bear side, current unprofitability, high forward P/E, and elevated debt levels pose substantial risks. The single most important tension is whether the company can successfully integrate AI to drive earnings growth to the $1.22 EPS consensus; if it does, the stock could re-rate higher, but any miss could trigger a sharp sell-off. Currently, the bull case has slightly stronger evidence given the low PEG and analyst upside, but the high forward multiple demands execution.
Bullish
- AI Acquisition Positions for Growth: The $270 million acquisition of Gleamer positions RadNet as a leader in AI-powered diagnostics, a high-growth segment. This strategic bet could drive revenue acceleration and margin expansion as AI tools are deployed across its 11,264-employee network.
- Strong Revenue Growth Trajectory: Estimated revenue of $3.05 billion for the current fiscal year implies robust top-line growth. The Imaging Center segment provides stable recurring revenue, while Digital Health adds incremental growth from AI solutions.
- Low PEG Ratio Suggests Undervaluation: With a PEG ratio of 0.38x, the stock appears undervalued relative to its expected earnings growth. This metric implies that the market has not fully priced in the anticipated earnings recovery, offering upside potential.
- Positive Analyst Sentiment with Upside: The consensus analyst target of ~$88.80 implies +29% upside from the current price of $68.75. With 4 analysts covering, the bullish outlook is supported by expected EPS growth to $1.22 from near-zero trailing earnings.
Bearish
- Unprofitable on GAAP Basis: Trailing EPS is -$0.0035 with a net margin of -0.91%, indicating the company is not yet profitable. The reliance on forward estimates for a turnaround introduces uncertainty, especially if AI investments take longer to yield returns.
- High Valuation on Forward Earnings: The forward P/E of 72.88x is extremely high, reflecting optimistic expectations for earnings growth. If the company fails to meet EPS estimates of $1.22, the stock could face significant multiple compression.
- Elevated Debt-to-Equity Ratio: With a debt-to-equity ratio of 1.71, RadNet carries moderate leverage. The $270 million Gleamer acquisition likely added debt, increasing financial risk and interest expense, which could pressure margins.
- Low Gross Margin Reflects Cost Pressures: Gross margin of only 4.45% is typical for imaging centers but leaves little room for error. Rising labor or equipment costs could further compress margins, delaying the path to profitability.
RDNT Technical Analysis
RadNet's 1-year price change of +23.54% reflects a sustained uptrend, though the stock has experienced significant volatility. Currently trading at $68.75, it sits at 80% of its 52-week range ($50.76–$85.84), indicating it is closer to the highs but not overextended. This positioning suggests bullish momentum but with room for further upside if resistance is broken. Over the past 1-month and 3-month periods, RadNet has surged 26.59% and 25.48%, respectively, sharply outperforming the S&P 500's -1.25% and +13.56% returns. This short-term acceleration diverges from the 6-month decline of -3.10%, signaling a potential trend reversal or mean reversion from the earlier pullback. The strong relative strength (1-month RS of 27.84) confirms recent buying pressure. The 52-week high of $85.84 acts as key resistance, while the 52-week low of $50.76 provides support. A breakout above $85.84 would signal a resumption of the long-term uptrend, while a breakdown below $50.76 could indicate further downside. With a beta of 1.364, RadNet is 36.4% more volatile than the market, amplifying both gains and losses for risk-aware investors.
Beta
1.36
1.36x market volatility
Max Drawdown
-38.6%
Largest decline past year
52-Week Range
$51-$86
Price range past year
Annual Return
+22.6%
Cumulative gain past year
| Period | RDNT Return | S&P 500 |
|---|---|---|
| 1m | +26.8% | +1.9% |
| 3m | +26.3% | +14.0% |
| 6m | -11.0% | +8.9% |
| 1y | +22.6% | +20.1% |
| ytd | -2.9% | +10.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RDNT Fundamental Analysis
Revenue trajectory is growing, supported by the company's expansion and AI initiatives. While specific quarterly revenue figures are not provided, the estimated revenue average of $3.05 billion for the current fiscal year implies a robust top line. The Digital Health segment, including AI acquisitions like Gleamer, is a key growth driver, while the Imaging Center segment provides stable recurring revenue. The company is currently unprofitable on a GAAP basis, with a trailing EPS of -$0.0035 and a net margin of -0.91%. However, gross margin stands at 4.45%, indicating low direct profitability typical of imaging centers, with operating margin also at 4.45%. The negative net income suggests high operating expenses or non-cash charges, but the forward EPS estimate of $1.22 implies a sharp turnaround to profitability. RadNet has a debt-to-equity ratio of 1.71, indicating moderate leverage, and a current ratio of 1.76, suggesting adequate liquidity. Free cash flow data is not available, but the PCF ratio of 17.95x implies positive cash flow generation. ROE is negative at -1.71%, reflecting the current net loss, but the expected earnings recovery should improve this metric.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RDNT Overvalued?
Since net income is negative (trailing EPS -$0.0035), the trailing P/E of -285.4 is not meaningful. Therefore, we use the price-to-sales (P/S) ratio of 2.63x as the primary valuation metric. The forward P/E of 72.88x implies the market expects a significant earnings recovery, with the gap between trailing and forward multiples reflecting anticipated growth. RadNet's P/S of 2.63x is above the industry average for medical diagnostics (typically ~1.5-2.0x), representing a premium of roughly 30-75%. This premium may be justified by its AI-driven growth strategy and market leadership, but it also prices in optimistic expectations. Historical P/S data is not provided, but the current multiple is likely elevated relative to historical levels given the recent AI narrative. The PEG ratio of 0.38x suggests the stock is undervalued relative to its expected earnings growth, though this relies on forward estimates that may be uncertain.
PE
-285.4x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
25.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: RadNet's primary financial risk is its current unprofitability, with a trailing EPS of -$0.0035 and net margin of -0.91%. The company carries a debt-to-equity ratio of 1.71, which may increase following the $270 million Gleamer acquisition, raising interest expense and financial leverage. Gross margin of just 4.45% indicates low direct profitability, making the business sensitive to cost inflation or reimbursement cuts. The reliance on forward EPS estimates of $1.22 for valuation introduces execution risk; if the turnaround stalls, the stock could re-rate sharply lower.
Market & Competitive Risks: The stock trades at a forward P/E of 72.88x, a significant premium to the broader market and diagnostic peers, making it vulnerable to multiple compression if growth disappoints. With a beta of 1.364, RDNT is highly correlated to market swings, amplifying downside in a bear market. The AI diagnostics space is competitive, with larger players like GE Healthcare and startups vying for market share. Regulatory risks around AI in healthcare could also slow adoption, while the recent Gleamer acquisition may face integration challenges.
Worst-Case Scenario: If RadNet fails to achieve the expected earnings turnaround—due to integration issues, margin pressure, or macro headwinds—the stock could fall to its 52-week low of $50.76, representing a -26% decline from the current price of $68.75. In a severe downturn, the historical max drawdown of -38.6% suggests a potential drop to around $42.20, implying a -39% loss. This scenario would likely involve missed EPS estimates, analyst downgrades, and a loss of investor confidence in the AI narrative.
FAQ
The primary risks are: 1) Financial: Current unprofitability (net margin -0.91%) and high debt-to-equity of 1.71, which could increase after the Gleamer acquisition. 2) Valuation: Forward P/E of 72.88x leaves little room for error; any earnings miss could trigger a sharp sell-off. 3) Competitive: The AI diagnostics space is crowded, and larger players may outspend RadNet. 4) Macro: With a beta of 1.364, the stock is highly sensitive to market downturns. The most severe risk is a failure to achieve the EPS turnaround, which could lead to a -26% decline to the 52-week low of $50.76.
The 12-month forecast is scenario-dependent. The base case (50% probability) sees the stock reaching the analyst average target of $88.80, driven by EPS of $1.22 and steady revenue growth. The bull case (30% probability) targets $85.84-$93.30, assuming successful AI integration and earnings beats. The bear case (20% probability) sees a decline to $50.76-$65.00 if integration fails or margins compress. The most likely scenario is the base case, supported by consensus estimates, but the high forward P/E means the stock is sensitive to execution. Investors should monitor quarterly results for confirmation of the earnings trajectory.
RDNT's valuation is a mixed picture. On a price-to-sales basis, the P/S ratio of 2.63x is above the industry average of 1.5-2.0x, indicating a premium of 30-75% that reflects optimism about its AI strategy. However, the PEG ratio of 0.38x suggests the stock is undervalued relative to its expected earnings growth of over 100% (from -$0.0035 to $1.22 EPS). The forward P/E of 72.88x is high but typical for companies with strong growth expectations. Overall, the market is pricing in a successful turnaround; if earnings materialize, the stock is undervalued, but if they disappoint, it is overvalued. Compared to its own history, the current multiples are elevated, reflecting the AI narrative.
RDNT presents a high-risk, high-reward opportunity. The stock offers +29% upside to the analyst average target of $88.80, supported by a low PEG ratio of 0.38x that suggests undervaluation relative to expected earnings growth. However, the forward P/E of 72.88x is extremely high, and the company is currently unprofitable with a trailing EPS of -$0.0035. The biggest downside risk is a failure to achieve the EPS turnaround, which could send the stock to the 52-week low of $50.76 (-26%). For growth-oriented investors with a long-term horizon and tolerance for volatility, RDNT could be a good buy if they believe in the AI narrative. Conservative investors should avoid it.
RDNT is better suited for long-term investment (3-5 years) given its growth stage and AI transformation thesis. The stock has a beta of 1.364, indicating high volatility, which makes short-term trading risky. The company pays no dividend, so returns depend entirely on price appreciation. The earnings turnaround to $1.22 EPS is expected within the next fiscal year, providing a catalyst for long-term holders. Short-term traders could capitalize on momentum, but the 52-week range of $50.76-$85.84 suggests significant swings. A minimum holding period of 12-18 months is recommended to allow the AI strategy to materialize.